Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Levobunolol
Drug ID BADD_D01267
Description A nonselective beta-adrenoceptor antagonist used in the treatment of glaucoma.
Indications and Usage For lowering intraocular pressure (IOP) and may be used in patients with chronic open-angle glaucoma or ocular hypertension.
Marketing Status approved
ATC Code S01ED03
DrugBank ID DB01210
KEGG ID D08115
MeSH ID D002040
PubChem ID 39468
TTD Drug ID D00IUG
NDC Product Code Not Available
UNII G6317AOI7K
Synonyms Levobunolol | Apo-Levobunolol | Apo Levobunolol | ApoLevobunolol | Betagan | Levobunolol Hydrochloride | Novo-Levobunolol | Novo Levobunolol | NovoLevobunolol | W-7000A | W 7000A | W7000A | ratio-Levobunolol | ratio Levobunolol | Ultracortenol | Vistagan | AKBeta | PMS-Levobunolol | PMS Levobunolol | PMSLevobunolol
Chemical Information
Molecular Formula C17H25NO3
CAS Registry Number 47141-42-4
SMILES CC(C)(C)NCC(COC1=CC=CC2=C1CCCC2=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Alopecia23.02.02.001--
Arrhythmia02.03.02.001---
Asthenia08.01.01.001---
Ataxia08.01.02.004; 17.02.02.001--
Atrioventricular block02.03.01.002---
Bradycardia02.03.02.002---
Bronchospasm10.01.03.012; 22.03.01.004--
Cardiac arrest02.03.04.001--
Cardiac failure congestive02.05.01.002---
Cerebral ischaemia17.08.01.005; 24.04.06.003--
Cerebrovascular accident17.08.01.007; 24.03.05.001--
Chest pain02.02.02.011; 08.01.08.002; 22.12.02.003---
Confusional state17.02.03.005; 19.13.01.001--
Conjunctivitis06.04.01.002; 11.01.06.012--
Depression19.15.01.001--
Diabetes mellitus05.06.01.001; 14.06.01.001---
Diarrhoea07.02.01.001--
Diplopia06.02.06.002; 17.17.01.005---
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007--
Dyspnoea02.11.05.003; 22.02.01.004--
Erythema multiforme10.01.03.015; 23.03.01.003--
Eyelid ptosis06.05.01.002; 17.17.02.004---
Feeling abnormal08.01.09.014---
Headache17.14.01.001--
Hypersensitivity10.01.03.003--
Hypoaesthesia eye06.01.01.007; 17.02.06.019---
Hypoglycaemia05.06.03.001; 14.06.03.001--
Hypotension24.06.03.002--
Iridocyclitis06.04.03.001---
Keratitis06.04.02.002--
The 1th Page    1 2    Next   Last    Total 2 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene